Bajcsay A, Kontra G, Récsán Z, Tóth J, Fodor J
Department of Radiotherapy; National Institute of Oncology, Budapest, H-1122 Hungary.
Neoplasma. 2003;50(6):459-64.
Occurrence of uveal metastases is higher, than the number of clinically diagnosed cases, furthermore all cases are not amenable to therapy. Treatment of primary cancer is permanently improving, as a result life prospective is better, with an increasing number of late distant metastases in an unusual location, as e.g. intraocular metastasis. As surgical approach is not suitable, and chemo/hormonal therapy often has a limited effect on intraocular dissemination, other treatment modalities are needed for the maintenance of visual acuity, and prevention of further deterioration of the quality of life. The study was made to evaluate the efficacy of external beam radiotherapy (EBRT) with lens-sparing techniques in the management of patients developing intraocular metastases (IOM). Between March 1994 and March 2002, 24 eyes of 17 patients with tumors metastatic to the eye were treated by EBRT. The female:male ratio was 8.5:1, age ranged between 37 and 74 years (mean: 56 years). The site of the primary tumor was: breast (11), lung (4) and others (2). The visual acuity at the beginning of irradiation was between 0.1-0.7 (mean 0.5) and a mean KPS of 60% was detected. The mean time elapsed from the diagnosis of primary tumor and recognition of metastasis was 38.9 months in case of breast, and 6.7 months in lung cancer. Eyes were treated by 6 MV photon beams, using a modified technique of Schipper's lens-sparing retinoblastoma treatment method. The following parameters were studied: visual acuity changes, local response rate, survival times from irradiation and ocular complications. Mean follow-up time was 24 months. Mean visual acuity improved two lines on the Snellen chart. The mean survival time after treatment of IOM was 21 months in breast and 4.9 months in lung cancer patients. Local response rate was 78%. No radiation cataract was observed. Only one patient developed radiation retinopathy 32 months after the treatment. External beam radiotherapy is recommended for the treatment of intraocular metastases to improve quality of life. In selected cases--especially breast cancer patients--lens-sparing technique is the treatment of choice.
葡萄膜转移瘤的发生率高于临床诊断病例数,此外并非所有病例都适合治疗。原发性癌症的治疗在不断改进,因此患者的预期寿命延长,但出现不常见部位远处转移(如眼内转移)的病例数却在增加。由于手术方法不适用,化疗/激素疗法对眼内播散的效果往往有限,因此需要其他治疗方式来维持视力并防止生活质量进一步恶化。本研究旨在评估采用晶状体保留技术的外照射放疗(EBRT)对眼内转移瘤(IOM)患者的治疗效果。1994年3月至2002年3月期间,17例发生眼部转移瘤的患者的24只眼接受了EBRT治疗。男女比例为8.5:1,年龄在37至74岁之间(平均56岁)。原发肿瘤部位为:乳腺(11例)、肺(4例)和其他部位(2例)。放疗开始时的视力在0.1至0.7之间(平均0.5),检测到的平均KPS为60%。乳腺癌患者从原发肿瘤诊断到转移瘤确诊的平均时间为38.9个月,肺癌患者为6.7个月。采用6 MV光子束,使用改良的Schipper晶状体保留视网膜母细胞瘤治疗方法对眼睛进行治疗。研究了以下参数:视力变化、局部缓解率、放疗后的生存时间和眼部并发症。平均随访时间为24个月。平均视力在斯内伦视力表上提高了两行。乳腺癌患者IOM治疗后的平均生存时间为21个月,肺癌患者为4.9个月。局部缓解率为78%。未观察到放射性白内障。仅1例患者在治疗后32个月发生放射性视网膜病变。推荐采用外照射放疗治疗眼内转移瘤以改善生活质量。在某些特定病例中——尤其是乳腺癌患者——晶状体保留技术是首选治疗方法。